Background: Congenital heart disease (CHD) is the most common human birth defect. Genetic causes for CHD remain largely unknown. GATA transcription factor 5 (GATA 5) is an essential regulator for the heart development. Mutations in the GATA5 gene have been reported in patients with a variety of CHD. Since misregulation of gene expression have been associated with human diseases, we speculated that changed levels of cardiac transcription factors, GATA5, may mediate the development of CHD.
Introduction
C ongenital heart disease (CHD) is the most common birth defect in humans, affecting about 1%-2% of live births. [1] Although a huge amount of genetic studies on humans and animals have been reported, only a few genes, such as GATA factor 4 (GATA4), T-box transcription factor 5 (TBX5) and NK2 transcription factor related, locus 5 (NKX2-5), have been implicated in a small portion of familial and sporadic CHD patients. [2, 3] Recent studies [4, 5] have demonstrated that morbidity and mortality are significantly higher in adult CHD patients than in general populations even after successful correction surgery. Late cardiac complications, such as heart failure, arrhythmia and sudden death, are main causes, which are likely due to genetic defects. [4, 5] Therefore, genetic studies of CHD are of basic and clinical importance.
The GATA transcription factor family consists of six members, GATA1-6, each of which contains a highly conserved DNA-binding domain that recognizes the sequence element (A/T)GATA(A/G). [6] GATA factors regulate differentiation, proliferation and survival of a variety of cell types. GATA1/2/3 genes are expressed in hematopoietic stem cells and related derivatives. GATA4/5/6 genes are expressed in various mesoderm and endoderm-derived tissues, including the heart. [7, 8] In the developing heart, GATA4, GATA5 and GATA6 genes are expressed in a partial overlapping but distinct spatial and temporal pattern. [7] The GATA5 gene is fi rst expressed in the precardiac mesoderm, then in the atrial and ventricular chambers and finally restricted to the atrial endocardium Novel and functional DNA sequence variants within the GATA5 gene promoter in ventricular septal defects Ji-Ping Shan, Xiao-Li Wang, Yuan-Gang Qiao, Hong-Xin Wan Yan, Wen-Hui Huang, Shu-Chao Pang, Bo Yan during the mouse embryonic development. GATA5 gene expression is also detected in the pulmonary mesenchyme and diverse smooth muscle cells. [9] Mice null for GATA5 are viable and lack of cardiac defects. Target deletion of the mouse GATA5 gene causes only female urogenital development. [10] Mice with compound heterozygous mutations for both GATA4 and GATA5 or both GATA5 and GATA6 died before birth or at perinatal stage with severe cardiac defects, including double outlet right ventricle and ventricular septal defect (VSD). [11, 12] Endocardial cell-specific inactivation of GATA5 in mice leads to hypoplastic hearts and partial formation of penetrant bicuspid aortic valve. [13] A recent study [14] indicates that GATA5 efficiently promotes the development of mouse embryonic stem cells into cardiomyocytes expressing cardiac troponin T gene. Therefore, GATA5 plays an essential role in the cardiac morphogenesis.
Mutations in the GATA5 gene have been reported in patients with various types of CHD, including VSD, tetralogy of Fallot and bicuspid aortic valve. [15] [16] [17] In familial cases, GATA5 mutations cause atrial septal defect, VSD and double outlet right ventricle. [18] GATA5 gene mutations have also been found in Down syndrome-associated atrioventricular septal defects. [19] In addition, GATA5 gene mutations cause familial atrial fi brillation. [20, 21] In different types of human cancer cells, such as gastrointestinal, lung and colorectal cancer, GATA5 gene promoter hypermethylation has been observed with reduced GATA5 levels. [22] [23] [24] [25] [26] Thus, we speculated that altered GATA5 gene expression levels, caused by DNA sequence variants (DSVs) within its promoter region, may mediate the development of CHD. In the present study, the promoter region of the human GATA5 gene was genetically and functionally analyzed in large groups of VSD patients and healthy controls.
Methods
Patients VSD patients (n=343, male 163, female 180, mean age 8.42 years), who were unrelated, were recruited from the Division of Cardiac Surgery, Jining Medical University Affiliated Hospital, Jining Medical University, China. All VSD patients had no family history of CHD. All VSD patients were diagnosed and confirmed by the following interventional procedures or open heart surgeries. Ethnic-matched healthy controls (n=348, male 283, female 65, mean age 5.25 years) were recruited from the same hospital. Controls with a family history of CHD were excluded. The procedures were in accordance with the ethical standards of the responsible committee on human experimentation of Jining Medical University Affiliated Hospital and with the Helsinki Declaration of 1964, as revised in 2000. Informed consents were obtained from participants or their guardians.
Sequence analysis
Peripheral leukocytes were isolated from vein blood and genomic DNAs were extracted. The GATA5 gene promoter of 836 bp (from -785 bp to +51 bp to the transcription start site at 61051026 of the human GATA5 genomic sequence) was generated with PCR with the following primers: GATA5-forward, 5'-AGTGCGAGCGGGACACGGTT-3', and GATA5-reverse, 5'-GAGCACTCACCAGCGGGCAG-3'. PCR primers were designed based on genomic sequence of the human GATA5 gene (NCBI: NC_000020.10). The PCR products were bi-directionally sequenced with BigDye ® Terminator v3.0 reagents and a 3730 DNA analyzer (Applied Biosystems, Foster city, CA, USA) and aligned with the wild type sequence of the GATA5 gene promoter.
Functional analysis
The DNA fragments of wild type and variant GATA5 gene promoters (836 bp, from -785 to +51 bp) were generated by PCR with the same set of PCR primers. A KpnI site was added to the GATA5 forward primer and a HindIII site to the GATA5 reverse primer. Expression constructs were generated by subcloning PCR products into KpnI and Hind III sites of a reporter vector (pGL3-basic) that express the luciferase gene. Designated expression constructs were transiently transfected into rat cardiomyocyte cells (H9c2), which were cultured with Dulbecco's modified Eagles medium (high glucose). Forty-eight hours post-transfection, the cells were collected and the luciferases activities were measured using dual-luciferase reporter assay system on a Glomax 20/20 luminometer (Promega, Madison, WI, USA). Expression construct expressing renilla luciferase gene (pRL-TK) was used as an internal control. Empty vector pGL3-basic was used as a negative control. The transcriptional activities of the GATA5 gene promoter were represented as ratios of luciferase activities over renilla luciferase activities. All the experiments were repeated three times independently.
Statistical analysis
The quantitative data were represented as mean±SE and compared by Student's t test. Frequencies of the DSVs within the GATA5 gene promoter in the VSD patients and controls were compared with SPSS v13.0. P<0.05 was considered statistically significant.
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Results
GATA5 gene promoters were bi-directionally sequenced in the VSD patients (n=343) and healthy controls (n=348). Distributions of the identified DSVs are summarized in Table. The DSVs' locations were indicated in Fig.1A . Two novel heterozygous DSVs (g.61051165A>G and g.61051463delC) were identified in three VSD patients, but not in the controls. DSV g.61051165A>G was found in an 11-year-old girl and a 31-year-old man, both with membranous VSD. DSV g.61051463delC was found in a 14-year-boy with a membranous VSD. In addition, a novel heterozygous DSV, g.61051227C>T, and three single-nucleotide polymorphisms (SNPs), g.61051279C>T (rs77067995), g.61051327A>C (rs145936691) and g.61051373G>A (rs80197101), were found in both VSD patients and controls with similar frequencies. In this population, SNPs, g.61051279C>T (rs77067995) and g.61051373G>A (rs80197101), were closely linked. Chromatograms of the novel DSVs were shown in Fig. 1B . The deletion DSV, g.61051463delC, was confirmed by subcloning the DNA fragments into expression vector and direct sequencing. Analysis of the GATA5 gene promoter region with TFSEARCH program (http://www.cbrc.jp/research/ db/TFSEARCH.html) suggested that the two novel DSVs (g.61051165A>G and g.61051463delC), which were only identified in VSD patients, did not alter binding sites of known transcription factors. To examine their transcriptional activities, expression constructs for wild type (pGL3-WT) and variant GATA5 gene promoters (pGL3-61051165G, pGL3-61051227T and pGL3-61051463delC) were generated. The constructs were transfected into H9c2 cells and dual-luciferase activities were measured. The results showed that the DSV, g.61051165A>G, significantly decreased the transcriptional activities of the GATA5 gene promoter (P<0.05). The DSV, g.61051463delC, significantly increased the transcriptional activities of the GATA5 gene promoter (P<0.01) (Fig. 2) . The DSV, g.61051227C>T, which was found in both VSD patients and controls, did not affect the GATA5 gene promoter activity (P>0.05).
Furthermore, the parents of the boy carrying g.61051463delC variant and the girl carrying g.61051165A >G variant were screened. The parents of the man carrying g.61051165A>G variant were not available for screening. Both 52-year-old father of the boy and 39-year-old father of the girl had the same GATA5 variants. Echocardiographic examination revealed that both fathers had a signifi cantly reduced diastolic function of left ventricles, though no VSD or other cardiac defects were found. These results suggested that the DSVs in GATA5 gene promoter may affect biological function of cardiomyocytes in adults. Taken together, these GATA5 variants may not play a causal role, but act as a risk factor for the development of VSD.
Discussion
Growing evidence has suggested that rare monogenic mutations and alleles play a major role in the etiology of common complex disorders. [27, 28] In the present study, we genetically and functionally analyzed the promoter region of the GATA5 gene in large groups of VSD patients and controls. Two novel heterozygous DSVs were found within the GATA5 gene promoter in three VSD patients, but not in the controls. Functionally, these DSVs significantly altered the transcriptional activities of the GATA5 gene promoter in cultured cardiomyocytes. The fathers of the VSD patients carried the same GATA5 variants and had a significantly reduced diastolic function of left ventricles. Therefore, these GATA5 gene promoter DSVs may increase the susceptibility to VSD development as a risk factor, probably by changing GATA5 levels.
The human GATA5 gene has been mapped to chromosome 20q13.2-q13.3. [29] The promoter region of the human GATA5 gene has been partially characterized, which is lack of TATA elements. An E-box within the proximal region of the GATA5 gene promoter (-164 to -159 bp upstream to the transcription start site) has been identified, through which upstream stimulatory factor 1 activates GATA5 gene expression. [30] In mice, the DNA fragment (from -150 bp to +311 bp to the transcription start site) containing a conserved E-box exhibits the greatest promoter activity. [30] In the mouse GATA5 gene, an alternate promoter within its first intron has been reported, suggesting the complexity of the GATA5 gene expression and regulation. [31] In differentiating human colon cancer cells, the GATA5 gene is upregulated, suggesting that GATA5 gene expression could be induced. [32] In this study, we identifi ed the DSVs within the GATA5 gene promoter, through which GATA5 gene expression may be manipulated with genetic or pharmaceutical approaches.
Misregulation of gene expression programs has been implicated in a broad range of human diseases, including cancer, inflammation, diabetes and cardiovascular diseases. [33] Heart development is strictly controlled by a conserved network of cardiac transcription factors, Fig. 2 . Transcriptional activities of the wild type and variant GATA5 gene promoters. GATA5 gene expression constructs were transfected into H9c2 cells and dual-luciferase activities were measured. The transcriptional activity of wild type GATA5 gene promoter was designated as 100%. The data were represented as mean±SE from three independent transfection experiments, in triplicate. Lane 1, pGL3-basic, a negative control; 2, WT, wild type; 3, pGL3-61051165G; 4, pGL3-61051227T, which was used as an internal negative control; 5, pGL3-61051463delC. *: P<0.05, compared to pGL3-WT; †: P<0.01, compared to pGL3-WT.
Relative activities (%) [34] For example, NKX2-5 and cardiac-myosin heavy chain genes have been demonstrated to be directly regulated by GATA5. [35] [36] [37] [38] GATA5 interacts with GATA4 and GATA6 in the outfl ow tract formation. [11] GATA5 cooperates with GATA4 in regulating the cardiomyocyte proliferation. [12] In the developing heart, GATA5 directly interacts with TBX20 and P300 cofactor in regulation of gene expression. [39, 40] In the differentiation of cardiogenic precursors into endothelial endocardial cells, GATA5 and nuclear factor of activated T cells c (NF-ATc) synergistically activate cardiac gene expression. [41] NF-ATc has been shown to be essential for endocardial development. [42, 43] As a critical factor for heart development, decreased or increased GATA5 levels may interfere with cardiac gene regulatory network, leading to the development of CHD.
In conclusion, two novel and heterozygous DSVs were identified in VSD patients, which significantly altered transcriptional activities of the GATA5 gene promoter. Our fi ndings suggested that these DSVs may increase the susceptibility to the development of VSD as a risk factor. Genetic and pharmaceutical manipulation of GATA5 gene expression may provide some insight into designing novel and personalized therapies for adult patients with CHD.
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